---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-013290"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T11:16:01.760551+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sangamo cuts 27% of US workforce, restructures toward neurology and Fabry; EVP departs

## Summary
- US workforce reduced by ~120 roles (~27%); expects ~$31M annualized cost savings from restructuring.
- EVP Technical Operations R. Andrew Ramelmeier to leave July 10, 2023; Phillip Ramsey appointed Head of Technical Ops.
- Preliminary Q1 cash position expected to fund operations for at least 12 months; full Q1 results due by May 10, 2023.
- Strategic focus on Nav1.7 (IND 2024), prion (IND 2025), Fabry Phase 3 trial, and TX200 CAR-Treg; pauses partnered programs.
- One-time restructuring costs estimated at $5M-$7M, primarily in Q2 2023; reduces internal manufacturing and allogeneic footprints.

## SEC filing metadata
- accession: 0001628280-23-013290
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/0001628280-23-013290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/sgmo-20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-013290
- JSON: https://secwatch.observer/filing/0001628280-23-013290.json
- Plain text: https://secwatch.observer/filing/0001628280-23-013290.txt

## Key facts
- Earnings Releases
  SANGAMO THERAPEUTICS, INC reported preliminary financial results for first quarter 2023.
  - Period: first quarter 2023
  - Result: preliminary results
  source text: Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing preliminary financial results for the quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/0001628280-23-013290-index.htm
- Executive change
  R. Andrew Ramelmeier was terminated as Executive Vice President, Technical Operations at SANGAMO THERAPEUTICS, INC.
  - Action: terminated
  - Role: Executive Vice President, Technical Operations
  source text: the employment of R. Andrew Ramelmeier, Ph.D., Executive Vice President, Technical Operations, will terminate effective as of July 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/0001628280-23-013290-index.htm
- Restructurings & Charges
  SANGAMO THERAPEUTICS, INC announced a restructuring with charges of approximately $5 million to $7 million affecting United States workforce and California internal manufacturing and allogeneic research footprints (approximately 120 roles in the United States, or approximately 27% of its United States workforce).
  - Type: restructuring
  - Charge: approximately $5 million to $7 million
  - Affected area: United States workforce and California internal manufacturing and allogeneic research footprints
  - Headcount: approximately 120 roles in the United States, or approximately 27% of its United States workforce
  source text: in the elimination of approximately 120 roles in the United States, or approximately 27% of its United States workforce. Sangamo estimates that it will incur approximately $5 million to $7 million in cash-based expenses related to employee severance and notice period payments, benefits and related restructuring costs. Sangamo expects that the majority of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/0001628280-23-013290-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.